ArriVent and Alphamab Partner in $615.5 Million Collaboration for Novel ADC Cancer Treatments

ArriVent BioPharma, Inc. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. have entered into a significant $615.5 million collaboration agreement to develop and commercialize novel antibody-drug conjugates (ADCs) for cancer treatment. This partnership leverages Alphamab’s advanced ADC research platform and ArriVent’s global development and commercialization expertise, aiming to bring cutting-edge cancer therapies to market.

Announced on June 5, 2024, this agreement includes an upfront payment and potential milestone payments totaling up to $615.5 million. These payments are contingent on achieving specific regulatory, development, and sales milestones. Additionally, Alphamab will receive tiered sales royalties from ArriVent for each ADC product developed under this partnership. 

In a statement (PDF), Bing Yao, Chairman and Chief Executive Officer of ArriVent, said, “This collaboration strengthens and complements our pipeline with the potential to add multiple innovative new ADC programs and exemplifies our strategic model of identifying and developing potential first-and best-in-class product candidates from across the globe. We look forward to complementing the research and discovery capabilities of Alphamab with our global drug development and commercialization expertise to address the unmet needs of cancer patients.”

Related Article: MediLink and BioNTech Sign $1.8 Billion ADC Deal to Expand Cancer Therapy Innovations

Currently, the global ADC market is rapidly growing, with the market value at $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028. Several ADCs are already approved by regulatory agencies for treating cancers such as Hodgkin lymphoma and breast cancer. This collaboration aims to leverage this growth by developing new ADC candidates that could transform cancer treatment paradigms.

The collaboration between ArriVent and Alphamab brings opportunities to develop ADCs that can address unmet needs in oncology, providing patients with more effective and targeted treatment options. As oncology continues to evolve with advancements in molecular biology and targeted therapies, collaborations like this are crucial for accelerating the development and availability of next-generation cancer treatments.

Ting Xu, Ph.D., Founder, Chairman, and CEO of Alphamab Oncology, remarked, “ArriVent shares our passion for developing differentiated, clinically valuable, and globally competitive new drugs. This collaboration, based on Alphamab’s proprietary and clinically validated glycan-conjugation platform, combined with ArriVent’s deep knowledge in oncology and extensive development experience, provides us with the opportunity to work together to deliver important new oncology therapeutics to patients.”

Related Article: KriSan Biotech Expands ADC CrDMO Services to Global Biotech Companies

Author

Diana Shih